Results 151 to 160 of about 4,951 (199)

Broth Optical Density-Based Assessment for Phage Therapy: Turbidity Reduction, Antibacterial Virulence, and Time-Kill. [PDF]

Viruses
Abedon ST.
europepmc   +1 more source

Enzymatic property and stabilization mechanism of LysBT1, a novel polyextremotolerant endolysin with a C-terminal S-layer homology domain. [PDF]

Appl Environ Microbiol
Li Y, Luo K, Jiang C, Zhang Y, Yang Y, Yao Y, Li H, Gan F, Tang X-F, Tang B.   +9 more
europepmc   +1 more source

Cauda equina nerve root enhancement in adult intestinal toxemia botulism. [PDF]

BMC Neurol
Jiang R, Beland B, Shah V, Kang M, Pet DB.   +4 more
europepmc   +1 more source

[The bacteriolysis reaction in various intestinal infections].

Zhurnal mikrobiologii, epidemiologii i immunobiologii, 1969
M I, Levi, Iu Ia, Tendetnik, E Z, Rukhadze, N S, Priamukhina, E I, Vydrina   +4 more
openaire   +1 more source

Do microenvironmental changes in degenerative disc disease reflect in systemic circulation? A proteomic investigation. [PDF]

Clin Proteomics
Nayagam SM, Palraj ND, Eswaran M, Selvaraj G, Rajendran S, Ramachandran K, Arunachalam D, Tangavel C, K S SA, Raveendran M, Rajasekaran S.   +10 more
europepmc   +1 more source

Strategies of bacterial detection by inflammasomes. [PDF]

Cell Chem Biol
Jastrab JB, Kagan JC.
europepmc   +1 more source

Phage therapy could be key to conquering persistent bacterial lung infections in children. [PDF]

NPJ Antimicrob Resist
Sithu Shein AM, Hongsing P, Khatib A, Phattharapornjaroen P, Miyanaga K, Cui L, Shibuya K, Amarasiri M, Monk PN, Kicic A, Chatsuwan T, Higgins PG, Abe S, Wannigama DL.   +13 more
europepmc   +1 more source

Reply to Abedon, S.T. Dual-Receptor Recognition, Lysis Inhibition, Endolysin Release, and Reaction-Diffusion as Alternative Explanations. Comment on "Rojero et al. Bypassing Evolution of Bacterial Resistance to Phages: The Example of Hyper-Aggressive Phage 0524phi7-1. <i>Int. J. Mol. Sci.</i> 2025, <i>26</i>, 2914". [PDF]

Int J Mol Sci
Rojero M, Weaver-Rosen M, Serwer P.
europepmc   +1 more source

Moss-produced human complement factor H with modified glycans has an extended half-life and improved biological activity. [PDF]

Front Immunol
Tschongov T, Konwar S, Busch A, Sievert C, Hartmann A, Noris M, Gastoldi S, Aiello S, Schaaf A, Panse J, Zipfel PF, Dabrowska-Schlepp P, Häffner K.   +12 more
europepmc   +1 more source

Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections. [PDF]

Front Pharmacol
Fukaya-Shiba A, Ogata A, Kuribayashi R, Sakurai A, Suzuki K, Takadama S, Nishimura J, Uchiyama J, Ohge H, Takeuchi T, Tamaki H, Matsumoto T, Kiga K, Iwano H.   +13 more
europepmc   +1 more source